- Home
- CURI vs IMAB Comparison
CURI vs IMAB Comparison
Compare CURI & IMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CURI
- IMAB
- Stock Information
- Founded
- CURI 2015
- IMAB 2014
- Country
- CURI United States
- IMAB United States
- Employees
- CURI N/A
- IMAB N/A
- Industry
- CURI Movies/Entertainment
- IMAB Biotechnology: Pharmaceutical Preparations
- Sector
- CURI Consumer Discretionary
- IMAB Health Care
- Exchange
- CURI Nasdaq
- IMAB Nasdaq
- Market Cap
- CURI 101.0M
- IMAB 87.2M
- IPO Year
- CURI N/A
- IMAB 2020
- Fundamental
- Price
- CURI $2.09
- IMAB $1.09
- Analyst Decision
- CURI Strong Buy
- IMAB Strong Buy
- Analyst Count
- CURI 1
- IMAB 3
- Target Price
- CURI $3.00
- IMAB $8.00
- AVG Volume (30 Days)
- CURI 276.3K
- IMAB 672.9K
- Earning Date
- CURI 03-19-2025
- IMAB 03-13-2025
- Dividend Yield
- CURI 4.83%
- IMAB N/A
- EPS Growth
- CURI N/A
- IMAB N/A
- EPS
- CURI N/A
- IMAB N/A
- Revenue
- CURI $51,775,000.00
- IMAB $3,313,984.00
- Revenue This Year
- CURI N/A
- IMAB N/A
- Revenue Next Year
- CURI $9.18
- IMAB N/A
- P/E Ratio
- CURI N/A
- IMAB N/A
- Revenue Growth
- CURI N/A
- IMAB N/A
- 52 Week Low
- CURI $0.45
- IMAB $0.84
- 52 Week High
- CURI $3.00
- IMAB $2.08
- Technical
- Relative Strength Index (RSI)
- CURI 68.14
- IMAB 56.75
- Support Level
- CURI $1.53
- IMAB $1.00
- Resistance Level
- CURI $2.17
- IMAB $1.20
- Average True Range (ATR)
- CURI 0.15
- IMAB 0.12
- MACD
- CURI 0.07
- IMAB 0.02
- Stochastic Oscillator
- CURI 88.41
- IMAB 44.54
About CURI CuriosityStream Inc.
CuriosityStream Inc is a media and entertainment company. It offers premium video programming across the principal categories of factual entertainment, including science, history, society, nature, lifestyle, and technology. Its mission is to provide premium real entertainment that informs, enchants, and inspires. Its product and services are Direct to Consumer Business, Partner Direct Business, Bundled Distribution, Content Licensing, Enterprise Subscriptions, and Others. The majority of the revenue comes from the Direct to direct-to-consumer business.
About IMAB I-MAB
I-MAB is a clinical-stage biotech company. Along with its subsidiaries, it is principally engaged in discovering and developing transformational biologics in the fields of immuno-oncology and immuno-inflammation diseases in the People's Republic of China and other countries and regions. Its drug pipeline includes Uliledlimab (TJD5) which is an antibody for solid tumors, Ragistomig (TJ-L14B), and Givastomig (TJ-CD4B).